At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
pazopanib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination With Lapatinib in Adult Patients With Relapsed Malignant Glioma
In Brief
A Phase 2 clinical trial evaluating pazopanib and lapatinib for Glioma. Completed, enrolled 75 participants.
Detailed Summary
This study is being conducted to characterize the safety/tolerability of pazopanib and lapatinib when administered in combination with enzyme-inducing anticonvulsants in patients with recurrent Grade III or IV malignant gliomas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioma
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2006
Enrollment StartDec 2006
Primary CompletionDec 2009
TodayJul 2026
First PostedJul 11, 2006
Enrollment StartDec 1, 2006
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 20.0 years ago
Interventions
pazopanibdrug
Pazopanib is a novel compound being developed for the treatment of various cancers.
lapatinibdrug
Lapatinib is a novel compound being developed for the treatment of various cancers.